Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JTX-8064 (Anti-LILRB2) Monotherapy and Combo with Pimivalimab in Advanced Solid Tumors
NCT04669899Phase 2Completed
- Sponsor
- Jounce Therapeutics
- Start
- Jan 2021
- Primary completion
- Nov 2023
- Modality
- IgG Antibodies, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of JTX-8064 in solid tumor, ovarian cancer, clear cell renal cell carcinoma (ccRCC), triple-negative breast cancer (TNBC), head and neck squamous cell carcinoma (HNSCC), sponsored by Jounce Therapeutics. Started Jan 2021; status: completed.
02
Drugs
JTX-8064
03
Conditions
solid tumorovarian cancerclear cell renal cell carcinoma (ccRCC)triple-negative breast cancer (TNBC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04669899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04669899.